Market Closed -
Australian S.E.
08:38:14 21/06/2024 am IST
|
5-day change
|
1st Jan Change
|
0.006
AUD
|
0.00%
|
|
0.00%
|
-45.45%
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
32.01
|
11.52
|
6.401
|
17.92
|
7.682
|
38.03
|
Enterprise Value (EV)
1 |
28.7
|
9.755
|
4.701
|
16.32
|
5.514
|
34.75
|
P/E ratio
|
-22.4
x
|
-9
x
|
-10.8
x
|
-35
x
|
-30.1
x
|
-13.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
14.9
x
|
5.23
x
|
2.76
x
|
8.13
x
|
3.09
x
|
7.17
x
|
EV / Revenue
|
13.3
x
|
4.43
x
|
2.02
x
|
7.4
x
|
2.22
x
|
6.55
x
|
EV / EBITDA
|
-22.5
x
|
-7.54
x
|
-15.6
x
|
-124
x
|
-38.9
x
|
-20.1
x
|
EV / FCF
|
-18.8
x
|
-10
x
|
20.4
x
|
34.5
x
|
12.4
x
|
-63.8
x
|
FCF Yield
|
-5.32%
|
-9.95%
|
4.9%
|
2.9%
|
8.05%
|
-1.57%
|
Price to Book
|
7.41
x
|
3.73
x
|
2.5
x
|
9.53
x
|
4.07
x
|
2.51
x
|
Nbr of stocks (in thousands)
|
6,40,145
|
6,40,145
|
6,40,145
|
6,40,145
|
6,40,145
|
19,01,645
|
Reference price
2 |
0.0500
|
0.0180
|
0.0100
|
0.0280
|
0.0120
|
0.0200
|
Announcement Date
|
27/09/18
|
30/09/19
|
30/09/20
|
30/09/21
|
30/09/22
|
29/09/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
2.151
|
2.202
|
2.322
|
2.204
|
2.485
|
5.305
|
EBITDA
1 |
-1.275
|
-1.293
|
-0.3009
|
-0.132
|
-0.1416
|
-1.726
|
EBIT
1 |
-1.288
|
-1.311
|
-0.3257
|
-0.1497
|
-0.1525
|
-1.836
|
Operating Margin
|
-59.87%
|
-59.54%
|
-14.03%
|
-6.79%
|
-6.14%
|
-34.6%
|
Earnings before Tax (EBT)
1 |
-1.312
|
-1.266
|
-0.5931
|
-0.4957
|
-0.2365
|
-1.964
|
Net income
1 |
-1.312
|
-1.266
|
-0.5931
|
-0.4957
|
-0.2365
|
-1.94
|
Net margin
|
-60.98%
|
-57.48%
|
-25.55%
|
-22.49%
|
-9.52%
|
-36.57%
|
EPS
2 |
-0.002231
|
-0.002000
|
-0.000926
|
-0.000799
|
-0.000399
|
-0.001443
|
Free Cash Flow
1 |
-1.526
|
-0.9711
|
0.2305
|
0.4728
|
0.4436
|
-0.5448
|
FCF margin
|
-70.92%
|
-44.09%
|
9.93%
|
21.45%
|
17.85%
|
-10.27%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
27/09/18
|
30/09/19
|
30/09/20
|
30/09/21
|
30/09/22
|
29/09/23
|
Fiscal Period: June |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
3.31
|
1.77
|
1.7
|
1.6
|
2.17
|
3.29
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-1.53
|
-0.97
|
0.23
|
0.47
|
0.44
|
-0.54
|
ROE (net income / shareholders' equity)
|
-31%
|
-33.9%
|
-20.6%
|
-21.8%
|
-12.2%
|
-26.8%
|
ROA (Net income/ Total Assets)
|
-16.4%
|
-18.2%
|
-5.57%
|
-3.11%
|
-3.4%
|
-12.7%
|
Assets
1 |
7.977
|
6.968
|
10.64
|
15.93
|
6.951
|
15.34
|
Book Value Per Share
2 |
0.0100
|
0
|
0
|
0
|
0
|
0.0100
|
Cash Flow per Share
2 |
0.0100
|
0
|
0
|
0
|
0
|
0
|
Capex
1 |
0.17
|
0.06
|
0.03
|
-
|
0.01
|
0.06
|
Capex / Sales
|
7.97%
|
2.89%
|
1.45%
|
-
|
0.23%
|
1.07%
|
Announcement Date
|
27/09/18
|
30/09/19
|
30/09/20
|
30/09/21
|
30/09/22
|
29/09/23
|
|
1st Jan change
|
Capi.
|
---|
| -45.45% | 81.75L | | +34.14% | 5.15TCr | | -6.54% | 3.9TCr | | +34.92% | 3.89TCr | | -12.11% | 2.67TCr | | +12.62% | 2.61TCr | | -13.43% | 1.99TCr | | +43.73% | 1.37TCr | | +31.81% | 1.24TCr | | -4.54% | 1.17TCr |
Other Biotechnology & Medical Research
|